Relating to compounds of formula (i) wherein: X is CR1 and Cr3 or n is n X3, X4 or X5 is CR4 is CR5 or N n where at least one of X1, X3, X4 and X5 is N and not more than 2 between X1, X3, X4 and X5 are n N or X1 is CR1 and Cr3 is X3, X4 is a n or s Link X5 is CR5, N or s where at least one of X1, X3 and X5 and S N or s, not more than 2 between X1, X3 and X5 are n and not more than 1 between X3 and X5 are R1, R3, SR4 and R5 are independently h, halogeno, cyano, (C2 - 8) alquinilo, among others R6 (C1 - 8) alkyl, halogen - (alkyl (C1, C2) - (8) alquinilo, among others R2 is not Aromatic Heterocyclic and heteroaryl, among others E1 is - C (R7) (R8), among others E2 ((R11) (R12), among others R1 and R7, R8, R11 2 are independently h, halogeno, cyano, among others.A Preferred Compound is: [6 - (3 - amino - 5 - methyl - 3.6 - dihydro - 2H - [1,4] - 3 - oxazin - il) pyridin-2-yl] - amide acid 5 - bromo - pyridine - 2 - carboxylic acid, among others. Also referred to a Composition and a Pharmaceutical CombinationREFERIDO A COMPUESTOS DE FORMULA (I) DONDE: X ES CR1 O N X3 ES CR3 O N X4 ES CR4 O N X5 ES CR5 O N EN DONDE AL MENOS UNO DE X1,X3,X4 Y X5 ES N Y NO MAS DE 2 ENTRE X1, X3, X4, Y X5 SON N O X1 ES CR1 O N X3 ES CR3, N O S X4 ES UN ENLACE X5 ES CR5, N O S EN DONDE AL MENOS UNO DE X1, X3 Y X5 ES N O S, NO MAS DE 2 ENTRE X1, X3 Y X5 SON N Y NO MAS DE 1 ENTRE X3 Y X5 SON S R1, R3, R4 Y R5 SON INDEPENDIENTEMENTE H, CIANO, HALOGENO, (C2-8)ALQUINILO, ENTRE OTROS R6 ES (C1-8)ALQUILO, HALOGENO-(C1-8)ALQUILO, (C2-8)ALQUINILO, ENTRE OTROS R2 ES HETEROARILO O HETEROCICLICO NO AROMATICO, ENTRE OTROS E1 ES -C(R7)(R8)-, ENTRE OTROS E2 ES -C(R11)(R12)-, ENTRE OTROS R7, R8, R11 Y R12 SON INDEPENDIENTEMENTE H, CIANO, HALOGENO, ENTRE OTROS. ES UN COMPUESTO PREFERIDO: [6-(5-AMINO-3-METIL-3,6-DIHIDRO-2H-[1,4]-OXAZIN-3-IL)-PIRIDIN-2-IL]-AMIDA DEL ACIDO 5-BROMO-PIRIDINA-2-CARBOXILICO, ENTRE OTROS. REFERIDO ADEMAS A UNA COMPOSICION Y A UNA COMBINACION FARMACEUTICA
